151539-61-6

Basic information

• Product Name: (E)-8-(3,4-Methylenedioxystyryl)-1,3-dipropylxanthine hydrate
• Synonyms: (E)-8-(3,4-Methylenedioxystyryl)-1,3-dipropylxanthine hydrate
• CAS NO: 151539-61-6
• Molecular Formula: C20H22 N4 O4
• Molecular Weight: 382.41
• Mol File: 151539-61-6.mol

Chemical Properties

• Boiling Point: 618.3°Cat760mmHg
• Flash Point: 327.7°C
• Appearance: /
• Density: 1.339g/cm³
• Vapor Pressure: 3.24E-15mmHg at 25°C
• Refractive Index: 1.658
• PKA: 7.98±0.70(Predicted)
• CAS DataBase Reference: (E)-8-(3,4-Methylenedioxystyryl)-1,3-dipropylxanthine hydrate(CAS DataBase Reference)
• NIST Chemistry Reference: (E)-8-(3,4-Methylenedioxystyryl)-1,3-dipropylxanthine hydrate(151539-61-6)
• EPA Substance Registry System: (E)-8-(3,4-Methylenedioxystyryl)-1,3-dipropylxanthine hydrate(151539-61-6)

Safety Data

• Hazardous Substances Data: 151539-61-6(Hazardous Substances Data)

Usage

Uses

Used in Research Applications:
(E)-8-(3,4-Methylenedioxystyryl)-1,3-dipropylxanthine hydrate is used as a research compound for studying the adenosine pathway and its impact on various physiological processes. Its adenosine receptor antagonist activity makes it a valuable tool in understanding the role of adenosine in sleep, relaxation, and other related functions.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, (E)-8-(3,4-Methylenedioxystyryl)-1,3-dipropylxanthine hydrate is used as a starting material or intermediate in the synthesis of various drugs targeting adenosine receptors. Its ability to block adenosine receptors can be leveraged to develop medications for conditions where modulation of adenosine activity is desired.
Used in Nutraceutical Applications:
(E)-8-(3,4-Methylenedioxystyryl)-1,3-dipropylxanthine hydrate may also be used in the nutraceutical industry as an ingredient in supplements or energy-boosting products due to its stimulant properties. Its effects on adenosine receptors could potentially offer benefits for individuals seeking cognitive enhancement or increased alertness.

InChI:InChI=1/C20H22N4O4/c1-3-9-23-18-17(19(25)24(10-4-2)20(23)26)21-16(22-18)8-6-13-5-7-14-15(11-13)28-12-27-14/h5-8,11H,3-4,9-10,12H2,1-2H3,(H,21,22)/b8-6+

Relevant articles and documents

Antidepressants

The present invention relates to an antidepressant containing as an active ingredient a xanthine derivative or a pharmaceutically acceptable salt thereof, the xanthine derivative being represented by Formula (I) : STR1 in which R1, R2, and R3 represent independently hydrogen, lower alkyl, lower alkenyl; R4 represents cycloalkyl, --(CH2)n --R5 (in which R5 represents substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group; and n is an integer of 0 to 4), or STR2 (in which Y1 and Y2 represent independently hydrogen, halogen or lower alkyl; and Z represents substituted or unsubstituted aryl, STR3 (in which R6 represents hydrogen, hydroxy, lower alkyl, lower alkoxy, halogen, nitro, or amino; and m represents an integer of 1 to 3), or a substituted or unsubstituted heterocyclic group); and X1 and X2 represent independently O or S.

Therapeutic agent for Parkinson's disease

Agents for the treatment of Parkinson''s disease contain, as an active ingredient, a xanthine derivative or a pharmaceutically acceptable salt thereof. The xanthine derivative is represented by the formula: STR1 in which R 1, R 2 are R 3 are independently hydrogen, lower alkyl, lower alkenyl, or lower alkynyl; and R 4 represents cycloalkyl, --(CH 2) n --R 5 (in which R 5 represents substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group; and n is an integer of 0 to 4), or STR2 in which Y 1 and Y 2 represent independently hydrogen, halogen, or lower alkyl; and Z represents substituted or unsubstituted aryl, STR3 in which R 6 represents hydrogen, hydroxy, lower alkyl, lower alkoxy, halogen, nitro, or amino; and m represents an integer of 1 to 4, or a substituted or unsubstituted heterocyclic group; and X 1 and X 2 represent independently O or S.